



HAWAII DEPARTMENT OF HEALTH

COVID-19 Vaccine Information

Thursday, December 10



Governor David Ige



Lieutenant Governor Josh Green



Pfizer/BioNTech BNT162b2 Vaccine

- mRNA COVID-19 vaccine
- 2 dose injection, 21 days apart
- Phase 3 clinical trial began July 27, 2020
- Well-tolerated with most adverse effects resolving shortly after vaccination
- 95% effective
- FDA EUA Review: December 10, 2020



Pfizer Vaccine Efficacy

- Vaccine efficacy rate of 95% against confirmed COVID-19
- Vaccine efficacy rate over 94% in adults over 65 years of age
- Efficacy consistent across age, gender, race and ethnicity demographics



Pfizer Vaccine Safety

- Participants followed for a median of 2 months following 2nd dose of vaccine
- Vaccine well tolerated with most solicited adverse events (SAE) resolving shortly after vaccination
 - Most common SAE: injection site reactions, fatigue, headache, muscle pain, chills, joint pain, fever
 - Few Grade 3 SAEs greater than or equal to 2% in frequency (Gr 3 SAE = prevents daily routine activity) – fatigue, headache
- Older adults (over 55 years old) reported fewer and milder SAE following vaccination
- Similar safety profile across age groups, genders, ethnic and racial groups, participants with or without medical comorbidities, participants with or without evidence of prior SARS-CoV-2 infection at enrollment
- US FDA safety milestones achieved for EUA



Moderna mRNA 1273 Vaccine

- mRNA COVID-19 vaccine
- 2 dose injection, 28 days apart
- Phase 3 clinical trial began July 27, 2020
- Generally well-tolerated with majority of adverse effects mild to moderate
- 94.1% effective
- FDA EUA review: Dec. 17, 2020



Moderna Vaccine Efficacy

- Vaccine efficacy rate of 94.1% against confirmed COVID-19
- Efficacy consistent across age, race, ethnicity, gender demographics



Moderna Vaccine Safety

- Solicited adverse events indicate vaccine was well-tolerated
- Majority of adverse events mild or moderate in severity
- Grade 3 SAEs greater than or equal to 2%, generally short-lived (severe = prevents daily routine activity)
 - First dose – injection site pain
 - Second dose – fatigue, myalgia, arthralgia, headache, pain and erythema/redness at injection site
- US FDA safety milestones achieved for EUA



Dr. Elizabeth Char

Hawai'i State Department of Health Director



Hawaii Vaccine Operations – December 2020

Allocation:

45,825 Pfizer 1st doses

36,000 Moderna 1st doses

81,825 Allocation in December

Prioritization:



Healthcare workers at risk for exposure



Long-term care staff and residents



First responders and essential workers



Most hospitals have already enrolled



Working with counties on first responders and essential workers



Major General Kenneth Hara

- Adjutant General for the State of Hawai'i
-



Hilton Raethel

Healthcare Association of Hawai'i President & CEO



- HAH and HHEM are working closely with the Hawaii Dept. of Health to vaccinate essential healthcare workers.
- Hospitals are vaccinating their own employees, and in some cases, other healthcare workers in the community.
- There is a federal CVS/Walgreens partnership in place to work with skilled nursing and assisted living facilities to vaccinate workers and the residents in long term care.
(Moderna vaccine)



Dr. Kelley Withy

Director, Hawai'i/Pacific Basin Area Health
Education Education Center & COVID-19
vaccine clinical trial participant

